Targeting ACKR3/CXCR7 Enhances Platelet Anticoagulant Acylcarnitines and Modulates Procoagulant Function - PubMed
3 hours ago
- #Lipid Metabolism
- #Platelet Function
- #Thrombosis
- Targeting ACKR3/CXCR7 with an agonist (VUF11207) enhances the generation of anticoagulant long-chain acylcarnitines (LC-CARs) in platelets.
- CXCR7 activation preserves mitochondrial membrane integrity, reduces superoxide generation, and improves mitochondrial respiration in activated platelets.
- The agonist reduces platelet procoagulant functions by decreasing phosphatidylserine exposure, lipoprotein uptake via scavenger receptors, and thrombus formation in a murine model.
- It activates AMPK, leading to inhibitory phosphorylation of ACC, shifting metabolism toward lipolysis and increasing LC-CAR production.
- CXCR7 targeting lowers procoagulant lipids and thrombo-inflammatory mediators while raising plasma LC-CAR levels, suggesting therapeutic potential for thrombotic disorders.